Aadi Bioscience’s first product, FYARROTM (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus, ABI-009), is a form of sirolimus (rapamycin) bound to albumin that is based on similar technology as ABRAXANE® (nab-paclitaxel; Abraxis Bioscience acquired by Celgene Corp in 2010)
Albumin is accumulated in tumor tissues, either due to the leaky capillary system and defective lymphatic drainage of tumors  or through an active gp60/caveolae-mediated transport process across tumor blood vessel endothelium [2, 3]. Importantly, albumin is taken up by proliferating tumor cells via endocytosis and macropinocytosis, then catabolized by lysosomal degradation to support de novo protein synthesis, energy, and tumor growth . The accumulation of albumin in solid tumors provides potential rationale for albumin-based drug delivery systems to preferentially target tumors. The nab technology enables sirolimus to associate with albumin through non-covalent hydrophobic interactions to create a suspension of nanoparticles with an average size of < 100 nm
 Kratz F (2008). J Control Release 132, 171-183.
 Desai N et al (2006). Clin Cancer Res 12, 1317-1324.
 Minshall RD et al (2000). J Cell Biol 150, 1057-1070.
 Commisso C et al (2013). Nature 497, 633-637.
Differentiation vs. Existing mTOR Inhibitors
The nanoparticle albumin-bound (nab) platform drives multiple advantages for FYARROTM in animal models vs. currently approved mTOR inhibitors including: